InvestSMART

Saluda Medical, Inc. (ASX:SLD)

ALERT: Price-sensitive ASX Announcement for SLD
Current share price for SLD : $0.530 -0.06 (-10.17%)+
Announcement
Release
30 Apr 2026 8:17AM
Price at Release
$0.590
Full Release
download
Summary
Saluda Medical, Inc. has reported strong commercial progress in Q3 FY26, with significant growth in both U.S. and international revenues, driven by increased demand and physician engagement. The company experienced a 35% increase in U.S. revenues and a 31% rise internationally compared to the previous corresponding period. They continued to expand their sales force and trained representatives, achieving substantial physician engagement, which boosted the use of their neuromodulation platform, especially in high-volume ambulatory surgery centers. The company’s quarterly cash flow report, Appendix 4C, illustrates a disciplined financial management approach with an increase in total available funding to USD 171 million. Management remains confident in achieving an improved cash usage estimate for FY26 and has increased their FY26 revenue guidance to USD 87 million, reflecting a 24% growth over the prior year, backed by the adoption of the Evoke® System and EVA™ platform.
Key Points
  • Saluda Medical, Inc. reported 34% revenue growth in Q3 FY26.
  • U.S. revenues increased by 35%, and international revenues by 31%.
  • The sales force expanded with 89 trained representatives expected by FY26.
  • Appendix 4C shows disciplined financial management with USD 171 million in funding.
  • FY26 revenue guidance increased to USD 87 million, a 24% year-over-year growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.